This site is intended for healthcare professionals
Guidelines
  • Home
  • /
  • Guidelines
  • /
  • Rheumatoid arthritis
  • /
  • BSR and BHPR guideline for the prescription and mo...
Guideline

BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs

Read time: 1 mins
Last updated:26th Feb 2017
Status: Live
BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs - British Society for Rheumatology (BSR) & British Health Professionals in Rheumatology (BHPR)


The purpose of this guideline is to provide up-to-date, evidence-based recommendations for the safe use of non-biologic DMARDs in adults (>16 years old). The guideline is aimed at practitioners in both primary and secondary care settings. Specific areas that have been focused upon in this guideline include the following: recommendations regarding baseline screening prior to DMARD initiation; implications of co-morbid illness for DMARD prescribing; recommendations regarding monitoring for toxicity; management of DMARDs during intercurrent illness or surgery; and shared care guidelines.

 

Read full guideline